3.5. Proteomics-Based Re-Categorization Identified a Subgroup of Patients with PI3K-Activated DLBCL Whose Prognosis Could Be Further Defined by IQGAP3. This evidence concerns the gene IQGAP3 and diffuse large B-cell lymphoma.